Roy S Herbst

List of Publications by Citations

256 papers	44,044 citations	85 h-index	209 g-index
273 ext. papers	51,701 ext. citations	9.6 avg, IF	7.45 L-index

#	Paper	IF	Citations
256	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet, The*, **2016**, 387, 1540-1550	40	3964
255	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. *Nature* , **2014**, 515, 563-7	50.4	3354
254	Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. *JAMA - Journal of the American Medical Association*, **2003**, 290, 2149-58	27.4	2093
253	Lung cancer. *New England Journal of Medicine*, **2008**, 359, 1367-80	59.2	1920
252	Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. *Journal of Clinical Oncology*, **2004**, 22, 2184-91	2.2	1682
251	Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. *Journal of Clinical Oncology*, **2004**, 22, 785-94	2.2	1508
250	The biology and management of non-small cell lung cancer. *Nature*, **2018**, 553, 446-454	50.4	1499
249	Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. *Journal of Clinical Oncology*, **2004**, 22, 777-84	2.2	1496
248	TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. *Journal of Clinical Oncology*, **2005**, 23, 5892-9	2.2	1267
247	Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. *Journal of Clinical Oncology*, **2005**, 23, 5900-9	2.2	1250
246	Review of epidermal growth factor receptor biology. *International Journal of Radiation Oncology Biology Physics*, **2004**, 59, 21-6	4	859
245	Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. *Lancet Oncology, The*, **2016**, 17, 976-983	21.7	666
244	The BATTLE trial: personalizing therapy for lung cancer. *Cancer Discovery*, **2011**, 1, 44-53	24.4	660
243	An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. *Clinical Cancer Research*, **2013**, 19, 279-90	12.9	649
242	Programmed death ligand-1 expression in non-small cell lung cancer. *Laboratory Investigation*, **2014** , 94, 107-16	5.9	591
241	Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. *Journal of Clinical Oncology*, **2005**, 23, 8081-92	2.2	551
240	KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. *Clinical Cancer Research*, **2007**, 13, 2890-6	12.9	527

239	Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. *Journal of Clinical Oncology*, **2002**, 20, 3815-25	2.2	504
238	Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. *Journal of Clinical Oncology*, **2005**, 23, 2544-55	2.2	497
237	Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. *Cancer Discovery*, **2015**, 5, 860-77	24.4	476
236	Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. *Journal of Clinical Oncology*, **2005**, 23, 5474-83	2.2	421
235	Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. *Cancer*, **2002**, 94, 1593-611	6.4	391
234	Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. *Journal of Clinical Oncology*, **2003**, 21, 2574-82	2.2	381
233	Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. *Lancet Oncology, The* , **2010**, 11, 619-26	21.7	364
232	Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. *Journal of Clinical Oncology*, **2007**, 25, 4743-50	2.2	357
231	Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. *Journal of Clinical Oncology*, **2010**, 28, 2839-46	2.2	346
230	Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. *Journal of Clinical Oncology*, **2005**, 23, 5578-87	2.2	337
229	Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer. *New England Journal of Medicine*, **2020**, 383, 1711-1723	59.2	335
228	Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. *Journal of the National Cancer Institute*, **2012**, 104, 228-39	9.7	331
227	Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. *Lancet, The*, **2011**, 377, 1846-54	40	317
226	Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. *New England Journal of Medicine*, **2020**, 383, 1328-1339	59.2	317
225	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. *Cancer Discovery*, **2017**, 7, 1420-1435	24.4	302
224	ZD1839 (Iressa) in non-small cell lung cancer. *Oncologist*, **2002**, 7 Suppl 4, 9-15	5.7	287
223	Gefitinib--a novel targeted approach to treating cancer. *Nature Reviews Cancer*, **2004**, 4, 956-65	31.3	283
222	Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. *JAMA Oncology*, **2018**, 4, 210-216	13.4	277

221	American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *Journal of Clinical Oncology*, **2014**, 32, 1277-80	2.2	273
220	Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. *Journal of Clinical Oncology*, **2008**, 26, 1472-8	2.2	257
219	Phase I study of recombinant human endostatin in patients with advanced solid tumors. *Journal of Clinical Oncology*, **2002**, 20, 3792-803	2.2	256
218	Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. *Journal of Clinical Oncology*, **2007**, 25, 4270-7	2.2	254
217	Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. *Journal of Clinical Oncology*, **2008**, 26, 3351-7	2.2	249
216	Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. *Journal of Clinical Oncology*, **2005**, 23, 5464-73	2.2	249
215	To kill a tumor cell: the potential of proapoptotic receptor agonists. *Journal of Clinical Investigation*, **2008**, 118, 1979-90	15.9	247
214	Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. *Clinical Cancer Research*, **2019**, 25, 4592-4602	12.5	241
213	Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. *Nature Medicine*, **2019**, 25, 656-666	50.5	235
212	Objective measurement and clinical significance of TILs in non-small cell lung cancer. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	232
211	Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. *Journal of Clinical Oncology*, **2009**, 27, 3557-65	2.2	225
210	Angiogenesis and lung cancer: prognostic and therapeutic implications. *Journal of Clinical Oncology*, **2005**, 23, 3243-56	2.2	207
209	Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. *Journal of Clinical Oncology*, **2008**, 26, 5407-15	2.2	198
208	Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. *Clinical Cancer Research*, **2018**, 24, 1872-1880	12.9	181
207	Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. *Journal of Clinical Oncology*, **2007**, 25, 2369-76	2.2	173
206	Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. *Journal of Clinical Oncology*, **2002**, 20, 3804-14	2.2	172
205	Mode of action of docetaxel - a basis for combination with novel anticancer agents. *Cancer Treatment Reviews*, **2003**, 29, 407-15	14.4	171
204	Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. *Seminars in Oncology*, **2002**, 29, 27-36	5.5	167

203	Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. *Lancet Oncology, The*, **2020**, 21, 655-663	21.7	165
202	Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. *Clinical Cancer Research*, **2015**, 21, 1514-24	12.9	165
201	Scientific Advances in Lung Cancer 2015. *Journal of Thoracic Oncology*, **2016**, 11, 613-638	8.9	164
200	Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. *Clinical Trials*, **2008**, 5, 181-93	2.2	149
199	Assessing tobacco use by cancer patients and facilitating cessation: an American Association for Cancer Research policy statement. *Clinical Cancer Research*, **2013**, 19, 1941-8	12.9	143
198	Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. *Journal of Clinical Oncology*, **2005**, 23, 9089-96	2.2	141
197	Methodological and practical challenges for personalized cancer therapies. *Nature Reviews Clinical Oncology*, **2011**, 8, 135-41	19.4	138
196	Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. *Journal of Clinical Oncology*, **2011**, 29, 2312-8	2.2	132
195	Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. *Clinical Cancer Research*, **2004**, 10, 136-43	12.9	132
194	Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. *American Journal of Pathology*, **2000**, 157, 1893-903	5.8	130
193	Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. *Journal of Clinical Investigation*, **2011**, 121, 1313-28	15.9	124
192	Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. *Clinical Cancer Research*, **2003**, 9, 5532-9	12.9	117
191	CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. *Cancer Research*, **2013**, 73, 571-82	10.1	114
190	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. *Lancet Oncology, The*, **2019**, 20, 1109-1123	21.7	113
189	Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. *Expert Opinion on Investigational Drugs*, **2007**, 16, 239-49	5.9	112
188	Lung cancer in the era of precision medicine. *Clinical Cancer Research*, **2015**, 21, 2213-20	12.9	109
187	A first-in-human study of conatumumab in adult patients with advanced solid tumors. *Clinical Cancer Research*, **2010**, 16, 5883-91	12.9	109
186	The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*, **2016**, 34, 3638-3647	2.2	108

185	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) **2018**, 6, 75		107
184	Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1-Positive, Advanced Non-Small-Cell Lung Cancer in the KEYNOTE-010 Study. *Journal of Clinical Oncology*, **2020**, 38, 1580-1590	2.2	104
183	Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis. *Clinical Cancer Research*, **2019**, 25, 4663-4673	12.9	102
182	Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. *Journal of Thoracic Oncology*, **2015**, 10, S1-63	8.9	102
181	Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. *Clinical Cancer Research*, **2017**, 23, 370-378	12.9	101
180	Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. *Trends in Immunology*, **2018**, 39, 624-631	14.4	101
179	Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. *Lung Cancer*, **2004**, 44, 99-110	5.9	100
178	Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. *Journal of Clinical Oncology*, **2005**, 23, 2946-54	2.2	97
177	Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. *Journal of Clinical Oncology*, **2006**, 24, 190-205	2.2	95
176	Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. *Clinical Cancer Research*, **2018**, 24, 1562-1573	12.9	93
175	Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). *Oncologist*, **2018**, 23, 1407-e136	5.7	91
174	Dermatologic side effects associated with gefitinib therapy: clinical experience and management. *Clinical Lung Cancer*, **2003**, 4, 366-9	4.9	91
173	Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. *Journal of Clinical Oncology*, **2002**, 20, 4440-7	2.2	89
172	Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. *Clinical Cancer Research*, **2004**, 10, 4258s-4262s	12.9	87
171	Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy. *Clinical Cancer Research*, **2020**, 26, 970-977	12.9	83
170	IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. *Expert Opinion on Biological Therapy*, **2001**, 1, 719-32	5.4	82
169	Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. *Clinical Cancer Research*, **2009**, 15, 3600-9	12.9	81
168	Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology. *Journal of Clinical Oncology*, **2015**, 33, 952-63	2.2	80

167	Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. *Clinical Cancer Research*, **2007**, 13, 6175-81	12.9	78
166	Targeting the epidermal growth factor receptor in non-small cell lung cancer. *Clinical Cancer Research*, **2003**, 9, 5813-24	12.9	78
165	Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2016**, 14, 1430-1468	7.3	76
164	Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. *Molecular Cancer Therapeutics*, **2007**, 6, 471-83	6.1	76
163	Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: a comparison with 15O-labeled water-measured blood flow. *Journal of Nuclear Medicine*, **2008**, 49, 517-23	8.9	74
162	Integration of molecular profiling into the lung cancer clinic. *Clinical Cancer Research*, **2009**, 15, 5317-22	12.9	73
161	Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting. *JAMA - Journal of the American Medical Association*, **2018**, 320, 469-477	27.4	72
160	A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. *Journal of Thoracic Oncology*, **2010**, 5, 1054-9	8.9	72
159	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. *Journal of Thoracic Oncology*, **2020**, 15, 914-947	8.9	71
158	Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome. *Radiology*, **2005**, 237, 342-7	20.5	71
157	Small-cell lung cancer: prognostic factors and changing treatment over 15 years. *Clinical Lung Cancer*, **2012**, 13, 115-22	4.9	69
156	A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer. *Clinical Cancer Research*, **2014**, 20, 3921-30	12.9	66
155	B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. *Clinical Cancer Research*, **2017**, 23, 5202-5209	12.9	65
154	Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. *Journal of Clinical Oncology*, **2008**, 26, 1135-41	2.2	63
153	Therapeutic options to target angiogenesis in human malignancies. *Expert Opinion on Emerging Drugs*, **2006**, 11, 635-50	3.7	63
152	Erlotinib (Tarceva): An update on the clinical trial program. *Seminars in Oncology*, **2003**, 30, 34-46	5.5	63
151	E2F8 as a Novel Therapeutic Target for Lung Cancer. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	62
150	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers. *Science Translational Medicine*, **2017**, 9,	17.5	62

149	Treatment of Advanced Non-Small Cell Lung Cancer in 2018. *JAMA Oncology*, **2018**, 4, 569-570	13.4	60
148	IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. *Seminars in Oncology*, **2002**, 29, 18-30	5.5	60
147	Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. *Cancer Chemotherapy and Pharmacology*, **1998**, 41, 497-504	3.5	59
146	Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology. *Clinical Cancer Research*, **2015**, 21, 514-25	12.9	58
145	Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2018**, 13, 831-839	8.9	57
144	Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. *Journal of the National Cancer Institute*, **2010**, 102, 859-65	9.7	57
143	Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. *Journal of Clinical Oncology*, **2010**, 28, 4747-54	2.2	57
142	Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. *Journal of Thoracic Oncology*, **2008**, 3, 351-7	8.9	56
141	Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?. *Oncologist*, **2004**, 9 Suppl 1, 19-26	5.7	56
140	Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC) **2019**, 7, 65		54
139	Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. *Cancer Cytopathology*, **2013**, 121, 500-7	3.9	52
138	B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction. *Cancer Journal (Sudbury, Mass.)*, **2014**, 20, 281-9	2.2	52
137	"Quitting smoking will benefit your health": the evolution of clinician messaging to encourage tobacco cessation. *Clinical Cancer Research*, **2014**, 20, 301-9	12.9	51
136	Immune checkpoint therapy for non-small-cell lung cancer: an update. *Immunotherapy*, **2016**, 8, 279-98	3.8	50
135	ZD1839: targeting the epidermal growth factor receptor in cancer therapy. *Expert Opinion on Investigational Drugs*, **2002**, 11, 837-49	5.9	50
134	Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer. *Clinical Cancer Research*, **2016**, 22, 3713-7	12.9	49
133	Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. *Clinical Cancer Research*, **2013**, 19, 6967-75	12.9	49
132	ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection. *Clinical Lung Cancer*, **2018**, 19, e533-e536	4.9	48

131	Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. *Cancer Research*, **2011**, 71, 5512-21	19.1	48
130	Study of the media's potential influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial. *Journal of Clinical Oncology*, **2002**, 20, 3785-91	2.2	47
129	Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. *International Journal of Radiation Oncology Biology Physics*, **2007**, 69, 1534-43	4	46
128	Tobacco and cancer: an American Association for Cancer Research policy statement. *Cancer Research*, **2010**, 70, 3419-30	10.1	45
127	Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. *Clinical Cancer Research*, **2012**, 18, 1641-54	12.9	45
126	Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. *Lancet Oncology, The*, **2018**, 19, 101-114	21.7	45
125	VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. *Lung Cancer*, **2010**, 69, 337-40	5.9	44
124	Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor. *Clinical Cancer Research*, **2006**, 12, 3408-15	12.9	44
123	Angiogenesis inhibitors in clinical development for lung cancer. *Seminars in Oncology*, **2002**, 29, 66-77	5.5	43
122	Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. *Cancer*, **2001**, 92, 2364-73	6.4	43
121	Toward personalized treatment approaches for non-small-cell lung cancer. *Nature Medicine*, **2021**, 27, 1345-1356	50.5	43
120	The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer. *Clinical Cancer Research*, **2017**, 23, 5489-5501	12.9	41
119	JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer. *Molecular Cancer Therapeutics*, **2017**, 16, 2234-2245	6.1	41
118	Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. *International Journal of Radiation Oncology Biology Physics*, **2007**, 67, 870-8	4	41
117	Toxicities of antiangiogenic therapy in non-small-cell lung cancer. *Clinical Lung Cancer*, **2006**, 8 Suppl 1, S23-30	4.9	41
116	Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819. *Clinical Cancer Research*, **2012**, 18, 4004-12	12.9	40
115	Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research. *Clinical Cancer Research*, **2016**, 22, 1907-13	12.9	39
114	Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice. *Journal of Thoracic Oncology*, **2010**, 5, 940-9	8.9	39

113	Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. *Oncologist*, **2008**, 13, 1166-76	5.7	39
112	Current management of advanced non-small cell lung cancer: targeted therapy. *Seminars in Oncology*, **2005**, 32, 315-28	5.5	39
111	Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin. *Current Oncology Reports*, **2001**, 3, 131-40	6.3	39
110	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 195, 1661-1670	10.2	38
109	SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). *Journal of Thoracic Oncology*, **2019**, 14, 1847-1852	8.9	38
108	A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies. *BMC Cancer*, **2015**, 15, 171	4.8	36
107	Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. *European Journal of Cancer*, **2018**, 101, 201-209	7.5	36
106	Tobacco assessment in actively accruing National Cancer Institute Cooperative Group Program Clinical Trials. *Journal of Clinical Oncology*, **2012**, 30, 2869-75	2.2	36
105	Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. *Clinical Cancer Research*, **2004**, 10, 33-42	12.9	36
104	Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. *Cancer Chemotherapy and Pharmacology*, **2004**, 54, 308-14	3.5	35
103	Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. *Seminars in Oncology*, **2003**, 30, 30-8	5.5	35
102	Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials. *Clinical Cancer Research*, **2012**, 18, 638-44	12.9	34
101	SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). *Journal of Thoracic Oncology*, **2019**, 14, 1853-1859	8.9	33
100	A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. *Clinical Cancer Research*, **2003**, 9, 4108-15	12.9	33
99	Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice. *Molecular Cancer Therapeutics*, **2007**, 6, 2652-63	6.1	32
98	Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non-Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling. *Clinical Cancer Research*, **2020**, 26, 4360-4368	12.9	32
97	Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC. *Journal of Thoracic Oncology*, **2021**, 16, 1718-1732	8.9	32
96	SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). *Journal of Thoracic Oncology*, **2019**, 14, 1839-1846	8.9	31

95	A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. *Cancer*, **2009**, 115, 1713-22	6.4	31
94	Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer. *Clinical Cancer Research*, **2007**, 13, s4641-6	12.9	29
93	Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. *Clinical Lung Cancer*, **2004**, 6 Suppl 1, S7-S19	4.9	29
92	The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. *Cancer*, **2002**, 95, 340-53	6.4	29
91	The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer. *Journal of Thoracic Oncology*, **2019**, 14, 1046-1060	8.9	28
90	Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC. *Journal of Thoracic Oncology*, **2019**, 14, 793-801	8.9	28
89	The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. *Expert Opinion on Therapeutic Targets*, **2014**, 18, 1407-20	6.4	28
88	Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2019**, 14, 2084-2096	8.9	27
87	Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. *Clinical Lung Cancer*, **2006**, 7, 326-31	4.9	27
86	Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial. *Cancer Chemotherapy and Pharmacology*, **2001**, 48, 151-9	3.5	27
85	Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. *Clinical Cancer Research*, **2005**, 11, 678-89	12.9	27
84	Immunotherapy in Lung Cancer. *Hematology/Oncology Clinics of North America*, **2017**, 31, 131-141	3.1	26
83	Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research. *Clinical Cancer Research*, **2016**, 22, 2102-4	12.9	26
82	Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. *Lung Cancer*, **2002**, 37, 17-27	5.9	26
81	Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. *Lancet Oncology, The*, **2020**, 21, 1589-1601	21.7	26
80	Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. *Nature Reviews Clinical Oncology*, **2021**, 18, 625-644	19.4	23
79	Frontline immunotherapy for NSCLC - the tale of the tail. *Nature Reviews Clinical Oncology*, **2020**, 17, 73-74	19.4	22
78	New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs. *Clinical Cancer Research*, **2014**, 20, 4425-35	12.9	21

77	Tumor blood flow measured by perfusion computed tomography and 15O-labeled water positron emission tomography: a comparison study. *Journal of Computer Assisted Tomography*, **2009**, 33, 460-5	2.2	21
76	Use of novel second-line targeted therapies in non-small cell lung cancer. *Seminars in Oncology*, **2006**, 33, S9-16	5.5	21
75	A Burned-Out CD8 T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy. *Cancer Discovery*, **2021**, 11, 1700-1715	24.4	21
74	Phase I participantsQviews of quality of life and trial participation burdens. *Supportive Care in Cancer*, **2007**, 15, 885-90	3.9	20
73	Lung-MAP--framework, overview, and design principles. *Chinese Clinical Oncology*, **2015**, 4, 36	2.3	20
72	PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice. *Clinical Cancer Research*, **2020**, 26, 4186-4197	12.9	18
71	A Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum Stress. *PLoS ONE*, **2015**, 10, e0122628	3.7	18
70	Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer. *Journal of Thoracic Oncology*, **2013**, 8, 140-6	8.9	18
69	Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536. *Journal of Thoracic Oncology*, **2013**, 8, 1519-28	8.9	18
68	Targeted therapy in non-small-cell lung cancer. *Oncology*, **2002**, 16, 19-24	1.8	18
67	Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. *European Journal of Cancer*, **2013**, 49, 1815-24	7.5	17
66	Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer. *Clinical Cancer Research*, **2004**, 10, 8613-9	12.9	17
65	Targeted therapy using novel agents in the treatment of non-small-cell lung cancer. *Clinical Lung Cancer*, **2002**, 3 Suppl 1, S30-8	4.9	17
64	Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P).. *Journal of Clinical Oncology*, **2017**, 35, 102-102	2.2	17
63	A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): Interim safety and clinical activity in patients with urothelial carcinoma.. *Journal of Clinical Oncology*, **2017**, 35, 349-349	2.2	17
62	Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development. *Statistics in Biosciences*, **2016**, 8, 99-128	1.5	16
61	Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy. *Clinical Lung Cancer*, **2009**, 10, 20-7	4.9	16
60	Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012. *Clinical Lung Cancer*, **2009**, 10, 392-4	4.9	16

59	Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC. *Journal of Thoracic Oncology*, **2021**, 16, 1872-1882	8.9	16
58	Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). *Investigational New Drugs*, **2011**, 29, 499-505	4.3	15
57	Diminished but not dead: chemotherapy for the treatment of NSCLC. *Lancet Oncology, The*, **2016**, 17, 1464-1465	21.7	14
56	"Companion diagnostics": has their time come and gone?. *Clinical Cancer Research*, **2014**, 20, 4422-4	12.9	14
55	Chemotherapy for advanced non-small cell lung cancer. *Hematology/Oncology Clinics of North America*, **1997**, 11, 473-517	3.1	14
54	Gefitinib: current and future status in cancer therapy. *Clinical Advances in Hematology and Oncology* , **2003**, 1, 466-72	0.6	14
53	The role of growth factor signaling in malignancy. *Cancer Treatment and Research*, **2003**, 115, 19-72	3.5	13
52	ZD1839 (Iressa) in non-small-cell lung cancer. *Clinical Lung Cancer*, **2001**, 3, 27-32	4.9	13
51	The rationale and potential of combining novel biologic therapies with radiotherapy: focus on non-small cell lung cancer. *Seminars in Oncology*, **2003**, 30, 113-23	5.5	12
50	Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. *Journal of Thoracic Oncology*, **2021**, 16, 289-298	8.9	12
49	Antiangiogenic tumor therapy. *BioTechniques*, **2003**, 34, 1048-50, 1052, 1054 passim	2.5	11
48	Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D.. *Journal of Clinical Oncology*, **2017**, 35, 9055-9055	2.2	11
47	Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. *Journal of Thoracic Oncology*, **2021**,	8.9	11
46	A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). *Clinical Lung Cancer*, **2021**, 22, 170-177	4.9	11
45	Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion. *Clinical Lung Cancer*, **2014**, 15, 379-86	4.9	9
44	Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. *Journal of Cancer Research and Clinical Oncology*, **2009**, 135, 467-76	4.9	9
43	Angiogenesis inhibitors in lung cancer. *Current Oncology Reports*, **2002**, 4, 325-33	6.3	9
42	A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B.. *Journal of Clinical Oncology*, **2017**, 35, 9054-9054	2.2	9

41	The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting **2017**, 5,		8
40	Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial. *Cancers*, **2020**, 12,	6.6	8
39	Challenges and approaches to implementing master/basket trials in oncology. *Blood Advances*, **2019**, 3, 2237-2243	7.8	8
38	EGFR tyrosine kinase inhibitors in squamous cell lung cancer. *Lancet Oncology, The*, **2015**, 16, 872-3	21.7	7
37	Molecular targeted therapy for lung cancer. *Lancet, The*, **2005**, 366, 1507-8	40	7
36	Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly. *Cancer*, **2004**, 101, 1733-44	6.4	7
35	A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C.. *Journal of Clinical Oncology*, **2017**, 35, 9056-9056	2.2	7
34	Targeting vascular endothelial growth factor in patients with squamous cell lung cancer. *Journal of Clinical Oncology*, **2012**, 30, 1137-9	2.2	6
33	Multitargeted inhibitors in lung cancer: new clinical data. *Clinical Lung Cancer*, **2008**, 9 Suppl 3, S92-9	4.9	6
32	Pemetrexed in the treatment of advanced non-small-cell lung cancer: a review of the clinical data. *Clinical Lung Cancer*, **2004**, 5 Suppl 2, S67-74	4.9	6
31	Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non-small cell lung cancer?. *Cancer*, **2018**, 124, 4592-4596	6.4	6
30	Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042. *JTO Clinical and Research Reports*, **2021**, 2, 100205	1.4	6
29	Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial. *JAMA Oncology*, **2021**, 7, 1368-1377	13.4	6
28	Angiogenesis inhibition and lung-cancer therapy. *Lancet Oncology, The*, **2014**, 15, 124-5	21.7	5
27	Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of -altered non-small cell lung cancer. *Oncotarget*, **2018**, 9, 33995-34008	3.3	5
26	Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760) **2021**, 9,		5
25	Patient selection criteria and the FLEX Study. *Lancet, The*, **2009**, 373, 1497-8	40	4
24	BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2013**, 31, TPS8118-TPS8118	2.2	4

23	A step towards treating KRAS-mutant NSCLC. *Lancet Oncology, The*, **2013**, 14, 3-5	21.7	3
22	Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. *Clinical Lung Cancer*, **2021**, 22, 187-194.e1	4.9	3
21	Integration of targeted therapies in gemcitabine chemotherapy regimens. *Clinical Lung Cancer*, **2003**, 4, 217-23	4.9	2
20	Angiogenesis pathway inhibitors. *Cancer Chemotherapy and Biological Response Modifiers*, **2005**, 22, 225-45		2
19	PD3-3-4: Vandetanib in advanced NSCLC: an ongoing clinical evaluation program. *Journal of Thoracic Oncology*, **2007**, 2, S467-S468	8.9	2
18	Practical Considerations Relating to Routine Clinical Biomarker Testing for Non-small Cell Lung Cancer: Focus on Testing for Fusions. *Frontiers in Medicine*, **2020**, 7, 562480	4.9	2
17	Imaging in drug development. *Clinical Advances in Hematology and Oncology*, **2004**, 2, 268-9	0.6	2
16	Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). *JCO Oncology Practice*, **2021**, 17, e1821-e1829	2.3	1
15	SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study). *Clinical Lung Cancer*, **2021**, 22, 178-186	4.9	1
14	Management of Advanced Non‐Small Cell Lung Cancer **2018**, 99-115		1
13	Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer **2022**, 10, e004440		1
12	Cancer of the Lung **2017**, 1-30		0
11	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma **2022**, 10, e003956		0
10	Immune Checkpoint Inhibition in Lung Cancer **2018**, 333-344		
9	Targeted Therapy in Solid Tumors: Lung Cancer **2015**, 224-230		
8	Tyrosine-kinase inhibitors in oncology872-883		
7	AACR celebrates 50 years of tobacco research and policy. *Clinical Cancer Research*, **2014**, 20, 1709-18	12.9	
6	Highlights from: The 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology. *Clinical Lung Cancer*, **2009**, 10, 13-19	4.9	

5	Advances in the Treatment of Metastatic Non-Small-Cell Lung Cancer With Chemotherapy and Targeted Agents. *Clinical Pulmonary Medicine*, **2008**, 15, 352-358	0.3
4	2006 Highlights From: The Third International Association for the Study of Lung Cancer/American Society of Clinical Oncology/European Society of Medical Oncology International Conference on Molecular-Targeted Therapies in Lung Cancer Taormina, Sicily; November 2006. *Clinical Lung Cancer* , **2007**, 8, 234-241	4.9
3	Phase 1 Trials Today **2008**, 553-570	
2	Phase I Trials Today **2015**, 661-676.e2	
1	EGFR inhibition in NSCLC: the emerging role of cetuximab. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2004**, 2 Suppl 2, S41-51	7.3